Edesa Biotech Research, Inc.
514239 — The project will focus on the activities required for Phase 3 clinical trials/regulatory approval for their novel antibody treatment (EB05) targeting acute respiratory distress syndrome (ARDS), the most common cause of death in COVID-19 patients.